Immunology: WAO Online Lecture SeriesDescription
This self-directed learning series features expert lectures on the basic immunology mechanisms underlying allergic disease to help in patient diagnosis and treatment. As new immunotherapeutic strategies are being developed and adopted, it is becoming important to understand the rationale behind these therapies, and this requires an appreciation of the fundamentals of immunology.
If you are an allergy or clinical immunology physician, resident, or fellow-in-training, this will be an excellent refresher course. If you are a non-allergist practitioner who sees patients with allergic disease, you will find this to be a highly informative resource. The series is especially valuable for physicians in the emerging allergy societies of the World Allergy Organization.
The information disclosed by the faculty members of this activity is reported below for the review and information of activity participants.
Speaker and Planning Committee Disclosure Information
Richard F. Lockey, MD — University of South Florida College of Medicine, James A. Haley Veterans Administration. Dr. Lockey discloses lecture and/or consultant support from AstraZeneca, Curalogic, Dey, Merck, Novartis, Schering-Plough, and Takeda. He also discloses support for pharmaceutical research work from Alcon, AstraZeneca, Aventis, Baxter, Boehringer-Ingelheim, Dyax, Forest, Genentech, Glaxo Wellcome, Medimmune, Merck, Novartis, Pharming, Schering-Plougy, and Sepracor. Dr. Lockey is President, World Allergy Organization, and Past-President, American Academy of Allergy Asthma and Immunology.
Lanny J. Rosenwasser, MD — University of Missouri at Kansas City, Childrens Mercy Hospital. Dr. Rosenwasser discloses modest research support from Novartis, Genentech, AstraZeneca, Alcon, Regeneron, and Sanofi Aventis. Dr. Rosenwasser is the Secretary-General of the World Allergy Organization and Chief Editor of the World Allergy Organization Journal. Other organizational interests include the American Academy of Allergy Asthma and Immunology, Council of Medical Specialty Societies, and U.S. Pharmacopeia, and Federation of Clinical Immunology Societies.
Thomas Fleisher, MD — National Institutes of Health. Dr. Fleisher is a Past President of the Clinical Immunology Society and Robert A. Good Immunology Society for which he received stipends.
Michael A. Kaliner, MD — Institute for Asthma and Allergy. Dr. Kaliner discloses consulting and lecture relationships with Meda, Alcon, Ista, Merck, and Sepracor, and consulting for Novartis. He also discloses research funding for clinical studies from Astra, Glaxo, Aventis, Schering, Meda, Merck, Schering, and MedImmune. Dr. Kaliner is consultant for Strategic Pharmaceutical Advisors. He is also the Historian, Past-President, and a member of the Board of Directors of the World Allergy Organization.
James T. Li, MD, PhD — Mayo Clinic, Professor of Medicine. Nothing to disclose.
Mark Ballow, MD — SUNY Buffalo, Department of Pediatrics, and Women & Childrens Hospital, Buffalo, NY. Dr. Ballow discloses his posts on the advisory committees of Baxter Biotherapeutics and CSL Behring as well as research funding from Grifols Biologicals Inc for PI IGIV clinical phase IV trial. He holds a Le Bien visiting professorship with the Immune Deficiency Foundation/USIDNET.
Bruce Bochner, MD — Division of Allergy & Clinical Immunology, Johns Hopkins. Dr. Bochner discloses he is a member of the Glycomimetics, Inc., Scientific Advisory Board as well as consultant. He also discloses consulting interests with Pharmacyclics, Hoffman-LaRoche, Aduro Biotech, SIO Healthcare, Tarsa Therapeutics and Sanofi-Aventis. Dr. Bochner discloses research interests with the National Institutes of Health, Dana Foundation and Sanofi-Aventis. He is a member of the International Scientific Advisory Committee of AllerGen NCE, and he has editorial roles with the Journal of Allergy and Clinical Immunology, Clinical Translational Medicine, the Journal of Cell Death, and Asthma, Allergy Immunology. He is the Chief Editor of Allergy and Immunology and an editor of Adult Allergy and Asthma.
Anthony Bonilla, MD, PhD — Childrens Hospital, Boston, Harvard Medical School. Dr. Bonilla discloses modest consulting fees with ENTRA Pharmaceuticals and Prescription Solutions and editorial relationship with UpToDate. He also discloses research support from Talecris Biotherapeutics and his role on the Medical Advisory Committee, Consulting Immunologist Program of the Immune Deficiency Foundation.
David Chaplin, MD, PhD — Dept of Microbiology, University of Alabama-Birmingham. Dr. Chaplin discloses research funding from the National Institutes of Health.
Michael M. Frank, MD — Duke University Medical Center. Dr. Frank discloses consultant relationshipsrelated to study design and clinical trials with Dyax, Shire, CSL Behring, Pharming, and ViroPharma in their development of therapy for Hereditary Angioedema. He was the Chair of the Data Safety Monitoring Board for Dyax, and he has received a grant in aid in the past from Lev and CSL Behring.
Jordan Orange, MD, PhD — University of Pennsylvania School of Medicine. Dr. Orange discloses he is a consultant and speaker for Baxter, and CSL Bhering, is on the grants review committee of Octapharma USA and the Scientific Advisory Board of IBT Reference Laboratories. He also discloses he has received research funding from the National Institutes of Health. Dr. Orange is a member of the Membership Committee of the Clinical Immunology Society, the Medical Advisory Council of the Immune Deficiency Foundation, and the Advisory Committee of the US Immunodeficiency Network.
John Steinke, PhD — University of Virginia, Charlottesville, VA. Dr. Steinke discloses his role as co-investigator on the Allergic Disease Center grant award by the National Institutes of Health to the University of Virginia, and a research grant from Genetech awarded to colleague, Dr. Larry Borish.
Date of Original Release
15 March 2009
To verify your participation in online educational activities, you may be asked to provide your name, contact information, and/or other descriptors. The AAAAI will not release this information to outside entities. It may be used internally to inform you of other AAAAI educational activities. If you wish to have your information excluded from this process, please contact us at firstname.lastname@example.org.
WAO Contact Information
World Allergy Organization
555 East Wells Street, Suite 1100
Milwaukee, Wisconsin 53202-3823 USA
Phone: +1-414-276-1791 Fax: +1-414-276-3349